Trial Profile

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous, Oral and Subcutaneous Doses of Inno8 in Healthy Male Participants

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Inno-8 (Primary) ; Inno-8 (Primary) ; Inno-8 (Primary)
Indications Haemophilia A
Focus Adverse reactions
Acronyms VOYAGER1
Sponsors Novo Nordisk

Most Recent Events

05 Sep 2025 Number of arms changed from 11 to 14. Experimental: Cohort 1 (SSD): NNC0442-0344 A, Cohort 2 (SSD): NNC0442-0344 A and Placebo Comparator: SSD: Placebo added to study protocol. Primary endpoint "SSD: Number of treatment emergent adverse events" added to study protocol. Secondary outcome measured updated.
05 Sep 2025 Planned End Date changed from 4 Sep 2025 to 4 May 2026.
05 Sep 2025 Planned primary completion date changed from 2 Jun 2025 to 4 May 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com